2025年欧州臨床腫瘍学会（ESMO Congress 2025）では、3,000件以上のアブストラクトと100件を超えるレイトブレイキング発表が行われ、過去最多の臨床データが公開されました。 Biomedtracker […]
Share:
BiomedtrackerとDatamonitor Healthcareによる限定会期後サンプルレポートでは、オンコロジー領域の今後を大きく左右する注目の動向を厳選し、臨床試験、アセット、企業に関する重要なインサイトをお届けします。
サンプルレポートの内容
▼ESMO(European Society for Medical Oncology)についてはこちらから▼
European Society For Medical Oncology | ESMO
本ページのフォームをご提出いただくと、サンプルレポートを無料でダウンロードいただけます。
By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.
The report identifies pivotal clinical trial readouts, emerging therapeutic modalities, and shifts in standard of care across major tumor types. It also explores the strategic implications of these developments for business development, licensing, and portfolio planning.
By providing expert analysis of late-breaking data and updated likelihood of approval (LOA) metrics, the report helps BD&L and strategy teams assess asset competitiveness, identify partnering opportunities, and refine investment priorities.
The report covers data from leading pharma and biotech companies presented at ESMO 2025, including updates on high-impact assets across bladder, breast, lung, gastric, and other cancers. It includes LOA changes and commercial outlooks for over 50 oncology programs.
